# Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma

> **NCT01467921** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 68 (estimated)

## Conditions studied

- Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT01467921
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-12
- **Primary completion:** 2012-02
- **Final completion:** —
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2011-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01467921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01467921, "Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01467921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*